IMCR Immunocore Holdings: Enterprise Value-to-Revenue Multiple

Public company logo of immunocore.com (IMCR)

Immunocore Holdings plc (IMCR) is implementing laboratory screening automation to accelerate drug development. Stable demand for the treatment of rare tumors ensures high margins for its patented products. Comparing the company's price-to-sales ratio on GURU.Markets, we see the impact of Kimmtrak sales and new molecules; meanwhile, 2119.66 determines this parameter level, confirming the market valuation of TCR therapy's potential.

Company Value to Revenue: Immunocore Holdings (IMCR) for 11/23/2025 - 11/20/2026

immunocore.com - analytical breakdowns and key metrics (IMCR)

- share price and consensus valuation forecast:
- money and cash flow information:
Initial company analysis:Immunocore Holdings plc IMCR
Product sample of Immunocore Holdings plc

The EV/Sales multiple determines the market value of a business relative to its revenue, excluding the impact of debt load to provide an objective assessment of operational efficiency. This metric measures the density of investor expectations by filtering out the statistical noise of daily fluctuations. For Immunocore Holdings plc (IMCR), which develops immunotherapy through research alliances without capital mergers, the EV/Sales multiple reflects the value of pure organic growth. Analysis of the chart's dynamics allows for the identification of the risk of sharp drawdowns when the price deviates from the norm. This is a critical indicator of capital stability during the technological development phase.

Competitor analysis for Immunocore Holdings plc

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Janux Corp (JANX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Arcus Bio (RCUS)|Company Value to Revenue ZYME|TNGX - Enterprise Value-to-Sales Ratio|Company Value to Revenue IOVA (Iovance)|Enterprise Value-to-Revenue Coefficient IMTX|EV/Sales Multiple XNCR (Xencor)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP